(Lung Cancer) Imfinzi + Tremelimumab + Chemotherapy Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
On October 28, 2019, AstraZeneca announced: "Efficacy and safety results of anti-PD-L1 antibody Imfinzi (durvalumab) + anti-CTLA-4 antibody Tremelimumab + chemotherapy as first-line treatment in treatment-naive non-small cell lung cancer patients in POSEIDON Phase 3 clinical trial."
The POSEIDON Phase 3 clinical trial was a randomized trial conducted by international facilities dividing treatment-naive non-small cell lung cancer patients into three groups. Primary endpoints evaluated progression-free survival and overall survival for Imfinzi + chemotherapy group, with secondary endpoints evaluating Imfinzi + Tremelimumab + chemotherapy group progression-free survival and overall survival.
Primary endpoint results showed Imfinzi + chemotherapy group's progression-free survival had significant improvement compared to chemotherapy group, demonstrating clinical significance. Secondary endpoint results showed Imfinzi + Tremelimumab + chemotherapy group's progression-free survival had significant improvement compared to chemotherapy group, demonstrating clinical significance.
Regarding safety, adverse events in Imfinzi + chemotherapy group and Imfinzi + Tremelimumab + chemotherapy group were consistent with data from other current clinical trials, with no new adverse events occurring. Treatment discontinuation rates in both groups were similar to previous clinical trials.
Based on POSEIDON clinical trial results, José Baselga concluded: Treatment-naive non-small cell lung cancer patients treated with anti-PD-L1 antibody Imfinzi + anti-CTLA-4 antibody Tremelimumab + chemotherapy or Imfinzi + chemotherapy as first-line therapy both showed improved progression-free survival.
Primary and secondary endpoints (overall survival) results are expected to be released in 2020.
Note: The clinical trial data and medical information translated by "Medical Assistant" from overseas trials are not intended to promote participation in clinical trials or use of new drugs. Translation materials are for reference only, not as medication guidelines. Please consult healthcare professionals and refer to original content for accuracy.
#LungCancer #Imfinzi #Tremelimumab
-
Clinical Trial Drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase 2 Trial Results. (Lung Cancer) Non-Small Cell Lung Cancer with HER2 Gene Mutation: Effective with Enhertu? (Lung Cancer) Anti-B7-H3 Antibody DS-7300 Effective?
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1